Gerald P. Linette - Concepedia

Author

Gerald P. Linette

Washington University in St. Louis ORCID

Also Known As

G P Linette, G. Linette, G. P. Linette, G.P. Linette, GERALD P. LINETTE, Gerald Linette, Gerald P Linette, Gerald P. Linette, Haibo Zhao, J. Simpson

243

Publications

41.5K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis Memorial Sloan Kettering Cancer Center University of Pennsylvania Dana-Farber Cancer Institute Moffitt Cancer Center

About

Gerald P. Linette is an author at Washington University in St. Louis specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	50	10.5K
2	Health Sciences	13	17	3.9K
3	Allergy	2	2	46
4	Public Health	1	1	50
5	Biostatistics	1	1	50

Gerald P. Linette

Publications

38.2K

Citations

H-Index

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael A. Postow, Jason Chesney, Anna C. Pavlick, New England Journal of Medicine	2015	2.7K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Journal of Clinical Oncology	2015	2.5K
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells Beatriz M. Carreno, Vincent Magrini, Michelle Becker‐Hapak, Science ImmunologyImmune RegulationPathologyImmunodominanceImmunoediting	2015	1.3K
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, The Lancet Oncology MedicineMetronomic TherapyPathologyCancer TreatmentOncology	2016	1.2K
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Jedd D. Wolchok, Bart Neyns, Gerald P. Linette, The Lancet Oncology Pretreated Advanced MelanomaMedicineMelanomaClinical TrialsIpilimumab Monotherapy	2009	1.2K
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Gerald P. Linette, Edward A. Stadtmauer, Marcela V. Maus, Blood	2013	1.1K
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, The Lancet Oncology OncologyMelanomaClinical TrialsImmune Checkpoint InhibitorDermatology	2016	967
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Antoni Ribas, Richard Kefford, Margaret Marshall, Journal of Clinical Oncology	2013	811

Page 1